ID

14032

Descrição

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations; ODM derived from: https://clinicaltrials.gov/show/NCT01970865

Link

https://clinicaltrials.gov/show/NCT01970865

Palavras-chave

  1. 22/03/2016 22/03/2016 -
Transferido a

22 de março de 2016

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :


Sem comentários

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility ALK Positive Non Small Cell Lung Cancer NCT01970865

Eligibility ALK Positive Non Small Cell Lung Cancer NCT01970865

Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
evidence of histologically or cytologically confirmed diagnosis of locally advanced or metastatic nsclc (stage iv, ajcc v7.0) that carries an alk rearrangement, as determined by the food and drug administration (fda) approved fish assay (abbott molecular inc) or by immunohistochemistry (ihc) (ventana inc), or a ros1 rearrangement as determined by fish or rt pcr or next generation sequencing (ngs) via a local diagnostic test (ldt).
Descrição

nsclc

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0278987
alk+ nsclc patients must either be treatment naïve in the advanced setting or have had disease progression after 1or 2 previous alk inhibitor therapy(ies), as the last therapy given (phase 1 allows for intervening chemotherapy and more than 2 prior alk inhibitors).
Descrição

treatment naïve

Tipo de dados

boolean

Alias
UMLS CUI [1]
C3640935
ros1+ nsclc patients must either be treatment naïve in the advanced setting or have had disease progression after 1or 2 previous ros1 inhibitor therapy(ies), as the last therapy given (phase 1 allows for intervening chemotherapy and more than 2 prior ros inhibitors).
Descrição

ros1 inhibitor

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0812281
UMLS CUI [1,2]
C1999216
archival tissue sample available collected prior to enrollment.
Descrição

Tissue specimen

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1292533
all patients must have at least one measurable target extracranial lesion according to recist v1.1. in addition patients with asymptomatic cns metastases (including patients asymptomatic by means of stable or decreasing doses of steroids within the last 2 weeks prior to study entry) are eligible.
Descrição

extracranial lesion

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0580586
adequate bone marrow, pancreatic, renal, liver function.
Descrição

adequate bone marrow, pancreatic, renal, liver function.

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0005953
UMLS CUI [2]
C0232786
UMLS CUI [3]
C0232804
pregnancy test (for females of childbearing potential) negative at screening and at the baseline visit . male and female patients of childbearing potential must agree to use two highly effective methods of contraception from the time of the first negative pregnancy test at screening, throughout the study and for 90 days after the last dose of assigned treatment.
Descrição

Pregnancy test negative

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0427780
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. stereotactic or small field brain irradiation must have completed at least 2 weeks prior to study entry. whole brain radiation must have completed at least 4 weeks prior to study entry.
Descrição

radiation therapy

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1522449
systemic anticancer therapy completed within a minimum of 5 half-lives of study entry.
Descrição

anticancer therapy

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0920425
any one of the following currently or in the previous 3 months: myocardial infarction, congenital long qt syndrome, torsades de pointes, arrhythmias (including sustained ventricular tachyarrhythmia and ventricular fibrillation), right bundle branch block and left anterior hemiblock (bifascicular block), unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (chf ny heart association class iii or iv), cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism not adequately medically managed with anticoagulants; as well as bradycardia defined as <50 bpms. ongoing cardiac dysrhythmias of nci ctcae grade ≥ 2, symptomatic atrial fibrillation of any grade, or qtc interval >=481 msec at screening. right bundle branch block.
Descrição

Myocardial Infarction

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0027051
UMLS CUI [2]
C1141890
history of extensive, disseminated, bilateral or presence of grade 3 or 4 interstitial fibrosis or interstitial lung disease.
Descrição

Interstitial Lung Diseases

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0206062
current use or anticipated need for food or drugs that are known strong or moderate cyp3a4 inhibitors, inducers and cyp3a4 substrates with narrow therapeutic indices.
Descrição

cyp3a4 affecting substrates

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1142644
concurrent use of drugs that are cyp2c9 substrates with narrow therapeutic indices or those that are sensitive cyp2b6 substrates.
Descrição

Cytochrome p450 CYP2 enzyme

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1828473

Similar models

Eligibility ALK Positive Non Small Cell Lung Cancer NCT01970865

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
nsclc
Item
evidence of histologically or cytologically confirmed diagnosis of locally advanced or metastatic nsclc (stage iv, ajcc v7.0) that carries an alk rearrangement, as determined by the food and drug administration (fda) approved fish assay (abbott molecular inc) or by immunohistochemistry (ihc) (ventana inc), or a ros1 rearrangement as determined by fish or rt pcr or next generation sequencing (ngs) via a local diagnostic test (ldt).
boolean
C0278987 (UMLS CUI [1])
treatment naïve
Item
alk+ nsclc patients must either be treatment naïve in the advanced setting or have had disease progression after 1or 2 previous alk inhibitor therapy(ies), as the last therapy given (phase 1 allows for intervening chemotherapy and more than 2 prior alk inhibitors).
boolean
C3640935 (UMLS CUI [1])
ros1 inhibitor
Item
ros1+ nsclc patients must either be treatment naïve in the advanced setting or have had disease progression after 1or 2 previous ros1 inhibitor therapy(ies), as the last therapy given (phase 1 allows for intervening chemotherapy and more than 2 prior ros inhibitors).
boolean
C0812281 (UMLS CUI [1,1])
C1999216 (UMLS CUI [1,2])
Tissue specimen
Item
archival tissue sample available collected prior to enrollment.
boolean
C1292533 (UMLS CUI [1])
extracranial lesion
Item
all patients must have at least one measurable target extracranial lesion according to recist v1.1. in addition patients with asymptomatic cns metastases (including patients asymptomatic by means of stable or decreasing doses of steroids within the last 2 weeks prior to study entry) are eligible.
boolean
C0580586 (UMLS CUI [1])
adequate bone marrow, pancreatic, renal, liver function.
Item
adequate bone marrow, pancreatic, renal, liver function.
boolean
C0005953 (UMLS CUI [1])
C0232786 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Pregnancy test negative
Item
pregnancy test (for females of childbearing potential) negative at screening and at the baseline visit . male and female patients of childbearing potential must agree to use two highly effective methods of contraception from the time of the first negative pregnancy test at screening, throughout the study and for 90 days after the last dose of assigned treatment.
boolean
C0427780 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
radiation therapy
Item
radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. stereotactic or small field brain irradiation must have completed at least 2 weeks prior to study entry. whole brain radiation must have completed at least 4 weeks prior to study entry.
boolean
C1522449 (UMLS CUI [1])
anticancer therapy
Item
systemic anticancer therapy completed within a minimum of 5 half-lives of study entry.
boolean
C0920425 (UMLS CUI [1])
Myocardial Infarction
Item
any one of the following currently or in the previous 3 months: myocardial infarction, congenital long qt syndrome, torsades de pointes, arrhythmias (including sustained ventricular tachyarrhythmia and ventricular fibrillation), right bundle branch block and left anterior hemiblock (bifascicular block), unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (chf ny heart association class iii or iv), cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism not adequately medically managed with anticoagulants; as well as bradycardia defined as <50 bpms. ongoing cardiac dysrhythmias of nci ctcae grade ≥ 2, symptomatic atrial fibrillation of any grade, or qtc interval >=481 msec at screening. right bundle branch block.
boolean
C0027051 (UMLS CUI [1])
C1141890 (UMLS CUI [2])
Interstitial Lung Diseases
Item
history of extensive, disseminated, bilateral or presence of grade 3 or 4 interstitial fibrosis or interstitial lung disease.
boolean
C0206062 (UMLS CUI [1])
cyp3a4 affecting substrates
Item
current use or anticipated need for food or drugs that are known strong or moderate cyp3a4 inhibitors, inducers and cyp3a4 substrates with narrow therapeutic indices.
boolean
C1142644 (UMLS CUI [1])
Cytochrome p450 CYP2 enzyme
Item
concurrent use of drugs that are cyp2c9 substrates with narrow therapeutic indices or those that are sensitive cyp2b6 substrates.
boolean
C1828473 (UMLS CUI [1])

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial